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Abstract
Hypertension is one of the most prevalent cardiovascular diseases and its treatment requires multimodal therapeutic approaches.
This review aims to provide a summary and update on relevant evidence in hypertension research published in 2019/2020. These
include trials dealing with the prognostic effect of systolic and diastolic blood pressure values, the association between
hypertension and valve disease, reproducibility of masked and white-coat hypertension, and the prognostic importance of
ambulatory and night-time blood pressure measurements. Treatment of hypertension focusing on elderly patients but also the
potential cancer risk of thiazide diuretics, the valsartan recall, chronotherapy, and device-based hypertension therapy are discussed.
Introduction
Arterial hypertension is the most frequent modifiable risk
factor associated with cardiovascular morbidity and mortality
[1]. Despite the widespread availability of proven approaches
to lower blood pressure (BP), i.e. lifestyle modification and
pharmacotherapy, in many patients BP control to guideline
recommended targets is not achieved [2]. This review aims at
critically discussing and summarizing relevant trials in
hypertension research, which were published recently in
major journals. We discuss, among others, the independent
association of elevated systolic (SBP) and diastolic BP (DBP)
with cardiovascular (CV) outcomes, and the prognostic rele-
vance of 24-h and night-time BP measurements for estimation
of CV Risk. Current guidelines have recommended low-
ering SBP in most patients (<65 years) to targets of 120–130
mmHg. The treatment targets in patients of older age and the
neutral effects of lowering BP ≤ 140/90 mmHg in these
patients are reviewed. The Hygia trial investigated the impact
of bedtime versus morning dosing and found significant
improvements of CV morbidity and mortality associated with
bedtime administration of antihypertensive medication.
However, there remain major limitations to be considered
before this trial should change clinical practice. Finally, the
most recent trials in device-based hypertension treatments,
above all the results of the first pivotal study of catheter-based
renal denervation, are presented.
Epidemiology und pathophysiology
The Effect of systolic and diastolic blood pressure on
cardiovascular outcomes
High SBP and DBP associate with increased CV events.
However, it remained unclear whether either SBP or DBP
carries more prognostic information. This question was
addressed in a study, which evaluated data from an integrated
health care delivery system in the US. Between 2007 and
2016, more than 36 million office BP measurements were
analyzed from around 1.3 million people [3]. The study con-
firmed that both SBP and DBP increased the risk of CV events
such as myocardial infarction and stroke. A continuous burden
of SBP (≥140mmHg; hazard ratio (HR) per unit increase in z
score, 1.18; 95% confidence interval [CI], 1.17 to 1.18) and
DBP (≥90mmHg; HR per unit increase in z score, 1.06; 95%
CI, 1.06 to 1.07) independently predicted the composite out-
come. A J-curve relationship between DBP and the composite
outcome was detected. Elevated SBP had a greater prognostic
effect on stroke and myocardial infarction (Fig. 1). However,
DBP influenced the prognosis independently of SBP.
The 2017 American College of Cardiology and Amer-
ican Heart Association Guidelines on the management of
hypertension revised the definition of hypertension [4],
which has been defined as >130/>80 mmHg. Contrary, in
the 2018 European Guidelines, the definition remained
unchanged (>140/>90 mmHg) [2]. Against this background,
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the prevalence of hypertension according to the different
definition criteria were analyzed. The prevalence of hyper-
tension increased from 18.9% with a threshold of >140/90
mmHg to 43.5% with >130/80 mmHg. An SBP of >130
mmHg was present in almost 50% of the participants over
the age of 60 years (Fig. 2).
Clinical implication SBP and DBP are independently asso-
ciated with myocardial infarction and stroke, although SBP
has a greater prognostic effect. The J-curve relationship
between DBP and the composite outcome was strongly
influenced by age and coexisting conditions such as high SBP,
diabetes, coronary disease, smoking, and history of stroke.
Hypertension and heart valve disease
Hypertension not only increases the risk of stroke, myocardial
infarction, and renal failure [5] but also appears to be asso-
ciated with heart valve diseases such as aortic valve stenosis
and aortic valve insufficiency [6]. In a study from the UK, 5.4
million patients with unknown CV disease or aortic valve
disease at baseline were examined and followed for 9.2 years
[6]. A total of 20,680 patients (0.38%) were diagnosed with
aortic valve stenosis and 6440 patients (0.12%) with aortic
regurgitation. For each increase of 20mmHg in SBP, the
relative risk [RR] of aortic valve stenosis increased by 41%
(HR 1.41, 95% CI 1.38–1.45), and 38% for aortic regur-
gitation (HR: 1.38, CI 1.31–1.45) (Fig. 3), respectively. These
findings are associations and do not prove causation. There-
fore, a study which utilized Mendelian randomization meth-
ods analyzed data from 329,237 gene-typed subjects from the
UK (40–96 years of age). Mendelian randomization is a
method based on the natural distribution of gene variations
associated with certain diseases to investigate the association
between a risk factor and a disease [7]. This method can be
used to randomize participants based on polymorphisms
associated with lifelong exposure to influenceable risk factors
—in this case increased SBP. If an association between the
polymorphisms and the disease can be demonstrated, this
strongly suggests a causal relationship between exposure and
disease. The participants were recruited between 2006 and
2010. A total of 130 gene variants were selected for the
genetic determination of hypertension. A total of 1491
(0.45%) patients had aortic valve stenosis, 634 (0.19%) aortic
regurgitation and 1736 (0.53%) mitral regurgitation. With
each increase in SBP by 20mmHg, the RR for aortic valve
stenosis increased by 3.3-fold (odds ratio [OR] 3.26; 95% CI
1.50–7.10, p= 0.002), for aortic regurgitation by 2.5 (OR
2.59; 95% CI 0.75–8.92, p= 0.13), and for mitral valve
regurgitation by 2.2 (OR 2.19; 95% CI 1.07–4.47, p= 0.03),
respectively. An increase in SBP by 20mmHg was associated
with an almost 3-fold higher risk to develop any of the three
valvular diseases (OR 2.85; 95% CI 1.69–4.78, p < 0.001)
(Fig. 4). These data suggest that lifetime exposure to elevated
SBP appears to be associated with an increased risk of major
valvular heart disease.
Clinical implication The studies show an association
between hypertension and valvular heart disease outcomes.
It remains to be seen how BP control may affect the inci-
dence of heart valve disease progression.
Blood pressure measurement and target blood
pressure
Prognostic value of ambulatory blood pressure monitoring
and night-time blood pressure
The 2018 European Guidelines on the management of
arterial hypertension [2] recommend that the diagnosis of
Fig. 1 The effect of systolic and diastolic blood pressure on car-
diovascular outcomes. The relationship between systolic blood
pressure (solid line) and diastolic blood pressure (dashed line) z scores
and the risk of the composite outcome among participants with systolic
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Fig. 2 Prevalence of systolic blood pressure ≥130 or ≥140mmHg
depending on age. Systolic blood pressure measurements indicating
hypertension (systolic blood pressure ≥ 130 mmHg or ≥140 mmHg)
increased as a function of age [3].
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hypertension should not only be dependent on office BP
measurements but also on “out-of-office” measurements,
such as ambulatory blood pressure monitoring (ABPM) or
home blood pressure monitoring (HBPM). A study with
11,135 adults aged 54.7 years (49% women) from 13
cohorts investigated the association between mortality and
CV outcomes with the different methods of BP measure-
ment (office and conventional BP measurements, automated
measurements, 24-h SBP, day- and night-time BP) [8]. The
primary endpoints were mortality and a composite of CV
events consisting of cardiovascular mortality, non-fatal
cardiovascular events, heart failure, and stroke. The average
follow-up was 13.8 years, 43.7% of patients had high BP
(defined as >140/90 mmHg), 46.5% were on anti-
hypertensive drugs. A total of 2,836 (18.5 per 1000 person-
years) participants died and 2,049 (13.8 per 1000 person-
years) experienced a CV event. Both endpoints were sig-
nificantly associated with all single SBP indexes [8]
(p < 0.001). Higher 24-h and night-time BP measurements
were significantly associated with greater risks of death and
the composite CV outcome (Table 1, Fig. 5). For night-time
SBP, the HR for mortality was 1.23 (95% CI, 1.17–1.28)
and 1.36 (95% CI, 1.30–1.43) for CV events. For 24-h SBP,
the HR for mortality was 1.22 (95% CI. 1.16–1.28) and
1.45 (95% CI, 1.37–1.54) for CV events. In models that
adjusted for any of the other SBP indexes, the association of
night-time and 24-h SBP with the primary outcome
remained statistically significant (HRs ranging from 1.17
(95% CI, 1.10–1.25) to 1.87 (95% CI, 1.62–2.16)). For
every 20/10 mmHg increment of BP measured at night, the
risk of mortality increased by 23% and the risk of cardio-
vascular events by 36%.
Clinical implication 24-h and night-time BP measurements
were associated with greater risks of mortality and a com-
posite of CV outcome. Thus, they may be considered as the
most relevant measurements for estimating CV risk.
Reproducibility of masked and white-coat hypertension
Ambulatory BP measurements are essential for the detec-
tion of masked (normal office BP values, increased ambu-
latory BP values) and white-coat hypertension (increased
office BP values, normal ambulatory BP values). The
reproducibility of these BP phenotypes, however, is not
well known. In an analysis of 1664 hypertensive patients
who were treated with atenolol or lacidipine for four years
Fig. 3 The effect of systolic blood pressure on aortic valve diseases.
Shown are hazard ratios for aortic stenosis (a) and aortic regurgitation
(b) by categories of systolic blood pressure. Hazard ratios (HR) and
95% confidence intervals (CI) are displayed using floating absolute
risk. Square sizes are inversely proportional to standard error and
horizontal lines depict 95% confidence intervals. Models are adjusted
for age, sex, body mass index, smoking, year of initial blood pressure
measurement, total cholesterol, LDL, HDL, and practice-level index of
multiple deprivation [6].
Fig. 4 Association between systolic blood pressure increment and
valvular heart disease outcomes. The figure shows an increase in the
odds ratio per 20 mmHg increment in systolic blood pressure. Circles
show point estimation and vertical lines represent 95% CIs. Odds ratio
indicates hazard ratio in observational cohort studies and odds ratio in
mendelian randomization estimation. Data collected from observation
analyses and genetic studies [7].
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as part of the European Lacidipine Study on Atherosclerosis
(ELSA) [9], the reproducibility of masked and white-coat
hypertension was examined [10]. Both office and 24-h BP
were measured at baseline and every year of the 4-year
follow-up. After one year of treatment, the prevalence of
masked hypertension and white-coat hypertension was
21.1% and 17.8%, respectively (Fig. 6). The prevalence of
the phenotypes remained relatively constant throughout the
follow-up period, but the population of the cohort changed
significantly. Only about one-third of patients classified as
masked or white-coat hypertension according to one set of
office and ambulatory BP measurements maintained the
same classification at a subsequent set of measurements.
The number of patients diagnosed with masked or white-
Fig. 5 Incidence of mortality and cardiovascular outcomes,
adjusted for gender, age, nighttime and 24-h BP. Shown is the
incidence of mortality, adjusted for sex, age and 24-h systolic blood
pressure (A), cardiovascular outcomes, adjusted for sex, age and 24-h
systolic blood pressure (B), total mortality, adjusted for sex, age and
night-time systolic blood pressure (C) and cardiovascular outcomes,
adjusted for sex, age and night-time systolic blood pressure (D) over
follow-up in years based on systolic dipping ratio [8].
Table 1 Association of
outcomes with 24 h or night-




Outcomes Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P value
Total Mortality (n= 2836)
SBP index
Conventional 1.17 (1.10–1.25) <0.001 1.20 (1.14–1.26) <0.001
Automated office SBP 1.25 (1.17–1.34) <0.001 1.22 (1.17–1.29) <0.001
Measure times
24 h NA NA 1.24 (1.14–1.36) <0.001
Daytime 1.87 (1.62–2.16) <0.001 1.24 (1.17–1.31) <0.001
Nighttime 1.25 (1.11–1.41) <0.001 NA NA
Dipping ratio 1.43 (1.34–1.51) <0.001 1.21 (1.14–1.28) <0.001
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coat hypertension over the entire observation period was
4.5% and 6.2% only (Fig. 7).
Clinical implication The overall reproducibility of masked
and white-coat hypertension is low and suggests that regular
BP examinations (using different measurement modalities)
are necessary.
Target blood pressure values in elderly patients
According to recent guidelines, treatment of hypertension in
patients aged over 80 years should be initiated when BP is
≥160/≥90 mmHg (see Table 2) [2]. The 2018 European
Guidelines [2] recommend a BP treatment target of <130/
<80 mmHg in patients under 65 years of age [2]. The DBP
target is generally <80 mmHg regardless of age or comor-
bidities. In contrast to previous guidelines, the current
guidelines recommend that SBP should be targeted to a BP
range of 130–139 mmHg. These recommendations are
based on evidence indicating that the lowest risk of CV
events (especially cardiovascular death and congestive heart
failure) is observed at these values [11–13]. The 2018
European Guidelines emphasize that these values may even
be applied to patients over 80 years, provided that an SBP
between 130 and 140 mmHg is well tolerated.
The Berlin Initiative Study [14] examined the influence of
BP lowering in patients older than 70 years. The study
included 1628 patients with a mean age of 81 years who were
treated with antihypertensive drugs (636 exhibited normalized
BP < 140/<90mmHg). Patients with a BP < 140/90mmHg
had a 26% higher risk of all-cause mortality (HR 1.26; 95%
CI 1.04–1.54) than those whose BP above. The relative risk
was further increased by 40% in patients ≥80 years (HR 1.40;
95% CI 1.12–1.74), and likewise in patients with previous
CV events (HR 1.61; 95% CI 1.14–2.27). However, this risk
amplification was not observed in patients between 70 and 79
years (HR 0.83; 95% CI 0.54–1.27). The increased risk in the
elderly was particularly influenced by SBP values <130
mmHg (Fig. 8). The association between SBP and mortality
demonstrated in a U-shaped curve using 140mmHg as
reference. There was an increased risk with lower SBP values
that reached statistical significance at 125mmHg, while the
numerically increased risk with higher SBP values did not
reach statistical significance.
Clinical implication BP values ≤140/90 mmHg may be
associated with an increased risk of mortality in octogen-
arians or elderly patients with previous cardiovascular













Fig. 7 Proportion of patients diagnosed with masked or white coat
hypertension during the 4-year follow-up period. The percentage of
these patients decreases over time, which indicates a limited repro-
ducibility by frequently blood pressure measurements [10].
Table 2 Office blood pressure
thresholds for treatment [15].
Age group Office SBP treatment threshold (mmHg) Office DBP treatment
threshold (mmHg)
Hypertension + Diabetes + CKD + CCS +
Stroke/
TIA
18–65 ≥140 ≥140 ≥140 ≥140 ≥140 ≥90
65–79 ≥140 ≥140 ≥140 ≥140 ≥140 ≥90
≥80 ≥160 ≥160 ≥160 ≥160 ≥160 ≥90
Office DBP treatment
threshold (mmHg)
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Fig. 6 Prevalence of different hypertensive phenotypes over the 4-
year follow-up period. Masked uncontrolled hypertension (MUCH),
white-coat uncontrolled hypertension (WUCH), controlled hyperten-
sion, and uncontrolled hypertension are shown as % values during the
4 years of antihypertensive treatment in the European Lacidipine Study
on Atherosclerosis trial [10].
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treatment should be critically and individually evaluated,
especially in older patients.
Medical Therapy
Most patients with hypertension require lifelong medical
therapy to achieve optimal BP control. The 2018 European
Guidelines [2] equally recommend five classes of anti-
hypertensive drugs; these include ACE inhibitors (ACE-I),
angiotensin receptor blockers (ARB), beta blockers (BB),
calcium channel blockers (CCB), and diuretics (thiazides
and thiazide-like diuretics) [2].
Given the high rates of non-adherence to antihypertensive
medication, the treatment regime should be effective and
above all uncomplicated [15]. Hence, the importance of
combination treatment is particularly highlighted to improve
adherence to therapy and BP control. Therefore, the 2018
European Guidelines [2] recommend, especially in the con-
text of lower BP targets, to start antihypertensive therapy with
an initial dual fixed-dose combination of ACE-I or ARB+
CCB or diuretic (see Fig. 9). These combinations should be
the primary therapy for most patients. Exceptions are patients
with grade 1 hypertension (especially with SBP values <150
mmHg), low risk as well as elderly (≥80 years of age) or frail
patients. If BP is not controlled with a two-drug combination,
it is recommended escalating to a three-drug combination of
ACE-I or ARB+CCB+ diuretic (i.e. a triple combination)
(see Fig. 9). If BP still remains uncontrolled, despite triple
therapy in sufficient doses, treatment should be increased by
addition of spironolactone 25–50mg or, if not tolerated, other
diuretics such as amiloride or higher doses of other diuretics, a
BB, or an alpha-blocker should be added (see Fig. 9). Ther-
apy with BB is recommended especially for patients with
cardiac comorbidities (heart failure, angina pectoris, post-
myocardial infarction, atrial fibrillation, or younger women).
Thiazide—the first-choice antihypertensive drug?
The LEGEND project (Large-Scale Evidence Generation
and Evaluation across a Network of Databases) evaluated
data of 4.9 million patients from 9 different databases in the
USA, South Korea, Germany and Japan, in which treatment
Fig. 8 Primary and stratified
analyses of participants.
Forest-plot summarizing the
primary analysis and the
stratified analyses for blood
pressure values <140/90 or
>140/90 mmHg [14].
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[2].
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of hypertension was initiated with a single drug [16]. A total
of 55 safety and efficacy endpoints were examined. The
following three events were chosen as primary endpoints:
acute myocardial infarction, heart failure hospitalization and
stroke. Thiazide and thiazide-like diuretics showed better
primary effectiveness compared with ACE-I. The relative
risk reduction when treated with thiazide diuretics com-
pared with ACE-I was 17% (HR 0.83; 95% CI 0.74–0.95)
for stroke, 17% (HR 0.83; 95% CI 0.74–0.95) for heart
failure hospitalization and 16% (HR 0.84; 95% CI
0.75–0.95) for acute myocardial infarction, respectively.
There were no differences between ACE-I, ARB and CCB.
Significantly inferior to all classes were non-
dihydropyridine-CCB (diltiazem). Interestingly, the side
effects were comparable across all groups.
Clinical implication One of the limitations of this analysis
is the retrospective design. Physicians might have preferred
ACE-I over a diuretic in patients with increased CV risk.
That would explain why the effects on CV diseases in this
group are more significant compared with the ACE-I-group.
Furthermore, patients were treated with monotherapy,
which is no longer recommended. Lastly, information about
adherence to therapy and BP data are missing.
Hydrochlorothiazide and the increased the risk of cancer
Hydrochlorothiazide (HCT) is rarely used as a monotherapy
but is a frequent component of double or triple combination
preparations. The effectiveness of HCT compared with
other thiazide-like diuretics has been the subject of con-
troversial discussions [2, 17]. The warning published by the
European Medicines Agency (EMA) and the Federal
Institute for Drugs and Medical Devices in Germany
regarding the potential risk of basal cell carcinoma (BCC)
and squamous cell carcinoma (SCC) of skin should be
considered when prescribing HCT-containing drugs [18].
This letter was triggered by data from the Danish Cancer
Registry and the National Prescription Registry. These
studies from Denmark showed a cumulative dose-related
relationship between HCT and non-melanoma skin cancer
(NMSC) [19, 20]. The Danish study documented a dose-
dependent association between HCT and the risk for BCC,
ranging between 1.29 (95%CI 1.23–1.35) times for ≥50 g of
HCT and 7.7 (95%CI 5.7–10.5) times for ≥100 g of HCT
for SCC. As with any cohort study, only an association can
be proven, but no causality. There is also a lack of infor-
mation on the sun exposure of the patients and data on the
aggressiveness of the neoplasia.
Clinical implication The Drug Commission of the German
Medical Association does not recommend a general change
in therapy for all HCT-treated patients, but individual
examination and regular skin inspections. Chlorthalidone
and indapamide are possible alternatives, but no data are
available on the potential risk for skin cancer of these
thiazide-like diuretics [21].
Valsartan recall
Since early July 2018, products containing valsartan have
been recalled worldwide. The reason is the detection of a
known carcinogen, namely N-nitrosodimethylamine
(NDMA), which can be found in candesartan, irbesartan,
losartan, olmesartan, and valsartan. NDMA has been clas-
sified by the WHO International Agency for Research on
Cancer to be carcinogenic in humans [22]. The recall of
drugs containing valsartan from two Chinese manufacturers
that were contaminated with NDMA affected around 40%
of patients treated with valsartan in Germany. In the risk
assessment process, the EMA used a conservative assess-
ment of the possible cancer risk and came to the following
conclusion: If 100,000 patients would have received
NDMA-contaminated valsartan from Zhejiang Huahai
(manufacturing site where the highest levels of con-
taminants were found) every day for 6 years in the highest
dose, it could result in 22 additional liver cancers over the
lifetime of these patients. The presence of NDMA in these
drugs could lead to 8 additional cancer cases in 100,000
patients if they had taken the highest daily dose over 4 years
[23].
A study from Canada investigated the consequences of
the valsartan recall in more detail [24]. The study included
55,461 patients with a mean age of 76 years, 41% were
male, 95% had hypertension while 5% had heart failure.
Most patients (74%) were switched to a different ARB (not
valsartan). No alternative antihypertensive drug was pre-
scribed in 11% of the patients. This was accompanied by a
significant increase in the rate of emergency department
visits of +6% (p= 0.020) and hospitalization for stroke/
TIA of 8% (p= 0.037) (see Fig. 10) [24].
Fig. 10 Prescribing behavior after the Valsartan recall in Canada.
Most patients (74%) were switched to a different ARB (not 357 val-
sartan). No alternative antihypertensive drug was prescribed in 11% of
the patients [24].
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Clinical implication Due to the recall/warning regarding
valsartan, a relevant number of patients did not fill an
alternative prescription. Consequently, the number of
patients with unsatisfactory BP control and hospitalization
for hypertension and stroke/TIA increased.
Patiromer and spironolactone in the therapy of resistant
hypertension
Approximately 5–15% of all hypertensive patients have
resistant hypertension, which is associated with a sig-
nificantly increased CV risk [25]. Resistant hypertension is
defined as the failure of conservative treatment strategies to
lower office SBP and DBP values to <140 mmHg and/or
<90 mmHg despite optimal or best-tolerated doses of three
or more drugs, which should include a diuretic.
The PATHWAY-2 [26] trial was double-blind, placebo-
controlled, crossover trail, that compared different BP-
lowering medications in 335 patients with resistant hyper-
tension. In a preassigned, randomized order, participants were
treated for 12 weeks each with spironolactone (25–50mg),
bisoprolol (5–10mg), doxazosin modified release (4–8mg),
and placebo, in addition to their baseline BP medication.
During the first six weeks of each treatment cycle, the drugs
were initiated at the lower dose. After that, the drug doses
were doubled for the second half of the treatment cycle. The
average reduction in home SBP was greater with spir-
onolactone than with placebo (−8.7mmHg; 95% CI −9.7 to
−7.7; p < 0.0001), doxazosin (−4.0 mmHg; 95% CI −5.0 to
−3.0; p < 0.0001) or bisoprolol (−4.5 mmHg; 95% CI −5.5
to −3.5; p < 0.0001). The side effect profile of the substances
was comparable over the 3-month investigation period. Thus,
spironolactone has been recommended as a fourth-line ther-
apy in patients with uncontrolled hypertension. The use of
spironolactone, however, is often limited by hyperkalemia,
which is associated with increased mortality.
The oral potassium binder patiromer (a non-absorbable
potassium-binding polymer with calcium as an exchange
ion) lowers serum potassium levels and thus may be useful
in patients with medication-related hyperkalemia. In the
AMBER trial [27], patiromer was compared with placebo in
295 patients with therapy-resistant hypertension who were
treated with three or more antihypertensive substances. The
estimated glomerular filtration rate (eGFR) was 25–45 ml/
min/1.73 m2, and the serum potassium between 4.3 and 5.1
mmol/L. All patients received spironolactone (25–50 mg)
and patiromer (8.4 g) or placebo. After 12 weeks, therapy
with spironolactone could be continued in 66% of the
patients in the control group and 86% of the patients in the
patiromer group (group difference 19.5%, 95% CI
10.0–29.0; p < 0.0001) (Fig. 11). The cumulative dose of
spironolactone was 385 mg higher in the patiromer group
(p= 0.0021). The side effects were comparable between the
two groups. Although a higher dose of spironolactone was
administered over a longer period in the patiromer arm, the
BP change was not statistically significant between the
groups (−1.0 mmHg; 95% CI −4.4–2.4 mmHg; p= 0.58)
(Fig. 12).
Fig. 11 Time to discontinuation of spironolactone in patients with
and without patiromer. The proportion of patients who did not have
to discontinue spironolactone was higher in patients receiving patir-
omer compared with those receibing a placebo [27].
 
Mean change in BP -10.8 p<0.0001 Mean change in BP-11.7 p<0.0001 
Between-group difference change in BP 
-1.0 (95%CI -4.4 to 2.4); p=0.58 
Fig. 12 Automated,
unobserved systolic blood
pressure. Patiromer enables the
administration of spironolactone
in more patients. However, the
use of patiromer in addition with
spironolactone was not
associated with a significant
reduction of blood pressure after
12 weeks [27].
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Clinical implication Compared with placebo, patiromer
enables administration of spironolactone in more patients with
therapy-resistant hypertension and renal insufficiency. How-
ever, the use of patiromer in addition with spironolactone was
not associated with improved BP control. The long-term
effects of a therapy with patiromer (>12 weeks) are unknown.
Chronotherapy
The European Guidelines [2] do not recommend a preferred
administration-time. The Hygia Chronotherapy trial tested
whether night-time therapy in comparison to usual upon
awakening hypertension therapy exerts a favorable CV risk
reduction. The largest study in this context involved >40
Spanish care centers, which included a total of 19,084
hypertensive patients [28]. During an average follow-up of
6.3 years, 1752 participants experienced the primary car-
diovascular outcome consisting of CV death, myocardial
infarction, coronary revascularization, heart failure, or
stroke. An ambulatory BP measurement was performed for
48 h (!) to collect data on how BP differed during sleep.
Patients were randomized 1:1 to ingest their entire daily
dose of ≥1 hypertension medication at night-time or all of
them upon awakening. The RR reduction for various CV
events was significantly improved for night-time treatment
when compared with awakening treatment: 56% for CV
death (HR 0.44; 95%CI 0.34–0.56), 34% for myocardial
infarction (HR 0.66; 95% CI 0.52–0.84), 40% for coronary
revascularization (HR 0.60; 95% CI 0.47–0.75), 42% for
heart failure (HR 0.58; 95% CI 0.49–0.70) and 49% for
stroke (HR 0.51; 95% CI 0.41–0.63) (Fig. 13). Interestingly,
the reduction of BP was only marginally greater in the
night-time group (office SBP: 140 vs. 143 mmHg,
p < 0.001; office DBP: 82.4 vs. 81.4 mmHg, p < 0.001;
night-time SBP 118 vs. 114.7 mmHg, p < 0.001). There
were also significant differences regarding the substances
used in the groups (see Table 3), as this was not specified in
the study protocol. The limitations of the Hygia study
include the PROBE (prospective, randomized, open, blin-
ded endpoint) design, the difference in drug therapy across
groups, and the minimal difference in BP between the
groups, which can barely account for the enormous effects
on outcomes observed. Furthermore, treated and untreated
patients were included in the study without differentiation
or separate analysis of these subgroups. Moreover, there
was no reporting of the preliminary results of the trial before
publication and supplementary material providing more
details of the protocol and the full data analysis are lacking.
Indeed, some experts suggested from studying the protocol
that no proper randomization had been performed and the
database appeared as a summary database of multiple
smaller studies already completed, such as the MAPEC
study [29]. Despite the difficulties associated with 48 h of
ABPM, only 607 (3%) patients were excluded due to
inappropriate measurements. Of note, other studies were
unable to demonstrate the superiority of chronotherapy (e.g.
AASK [30]).
Clinical implication The Hygia study represents the largest
study that tested night-time antihypertensive treatment. In
this trial, chronotherapy was associated with a significant
reduction in endpoints (including death). However, there are
other studies that did not show an advantage of the chron-
otherapy. There are also major limitations in the study
design which questions the transfer of the results into rou-
tine clinical practice based on the trial’s results alone.
Renal denervation
After early clinical trials [31, 32] and registries [33] of renal
denervation showed promising results for the therapy to
reduce BP, the first sham-controlled SYMPLICITY HTN-3
[34] trial did not prove superiority for the BP-lowering
efficacy of renal denervation due to flaws in trial design and
conduct. The second-generation of sham-controlled trials
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Fig. 13 Survival of the two groups. Kaplan–Meier curve for the
combined endpoint (cardiovascular death, myocardial infarction, cor-
onary revascularization, heart failure and stroke) comparing treatment
upon awakening and at night-time [28].
Table 3 Antihypertensive therapy at the end of the examination
between groups [28].
Variable Awakening Night-time P between groups




1.80 ± 0.89 1.71 ± 0.93 <0.001
ARB, % 53.1 53.1 0.995
ACE,I % 25.3 23.4 0.002
CCB, % 32.7 36.8 <0.001
BB, % 22.0 17.5 <0.001
Diuretics, % 46.5 39.5 <0.001
Hypertension trials update
multicenter SPYRAL HTN-OFF-MED [35] and HTN-ON
MED [36] trials randomized patients with combined
systolic-diastolic hypertension in the absence or presence of
antihypertensive medication to renal denervation using the
multielectrode Spyral radiofrequency catheter or a sham
procedure. Both trials confirmed the feasibility and safety of
the procedure but were not prospectively powered for effi-
cacy endpoints. Recently, the results of the SPYRAL HTN-
OFF-MED Pivotal trial, which combined the data of the
pilot and pivotal trials using a Bayesian design, were pub-
lished. The trial was powered for change in mean 24-h and
office SBP between baseline and three months. While mean
24-h SBP did not change in the sham group (−0.6 mmHg;
95% CI −2.1 to 0.9), there was a significant reduction in the
renal denervation group across 24 h (−4.7 mmHg; 95% CI
−6.4 to −2.9). The primary endpoint of a significant
between-group difference of change in mean 24-h SBP
from baseline to 3 months (−3.9 mmHg; Bayesian 95%
credible interval: −6.2 to −1.6) was met (Fig. 14). After the
RADIANCE-HTN SOLO trial, which investigated the
ultrasound-based Paradise catheter, the SPYRAL Pivotal
trial is the second trial powered for efficacy showing the
superiority of renal denervation over sham. The procedural
safety was also confirmed by a meta-analysis of 50 trials
investigating radiofrequency-based renal denervation,
which in total included 5769 subjects with 10,249 patient-
years of follow-up, but identified only 26 (0.45%) patients
with renal artery stenosis or dissection [37].
Clinical implication The SPYRAL HTN-OFF MED Pivo-
tal trial demonstrated the superiority of catheter-based renal
denervation compared with sham control to safely lower BP
in the absence of antihypertensive medications.
Summary table
● SBP and DBP are independently associated with
myocardial infarction and stroke, although SBP has a
greater prognostic effect.
● Studies show an association between hypertension and
valvular heart disease outcomes. It remains to be seen
how BP control may affect the incidence of heart valve
disease progression.
● Twenty-four hours and night-time BP measurements
were associated with greater risks of mortality and a
composite of CV outcome. Thus, they may be
considered as the most relevant measurements for
estimating CV risk.
● The overall reproducibility of masked and white-coat
hypertension is low and suggests that regular BP
examinations (using different measurement modalities)
are necessary especially in these patients.
● BP values ≤140/90 mmHg may be associated with an
increased risk of mortality in octogenarians or elderly
patients with previous cardiovascular events.
● The risk-benefit assessment of an intensified BP
treatment should be critically and individually evalu-
ated, especially in older patients.
● Compared with placebo, patiromer enables the admin-
istration of spironolactone in more patients with therapy-
resistant hypertension and renal insufficiency.
● However, the use of patiromer in addition with
spironolactone was not associated with improved BP
control.
● The Hygia study represents the largest study that tested
night-time antihypertensive treatment. In this trial,
chronotherapy was associated with a significant
Fig. 14 Primary and secondary endpoint after renal denervation. Posterior distribution of between-group differences in (a) primary efficacy
endpoint (24-h systolic blood pressure) and (b) secondary effectiveness endpoint (office systolic blood pressure). BCI Bayesian 95% credible
interval, SBP systolic blood pressure [35].
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reduction in endpoints (including death). However, there
are other studies that did not show an advantage of the
chronotherapy. There are also major limitations in the
study design which question the transfer of the results
into routine clinical practice based on the trial’s results
alone.
● SPYRAL HTN-OFF MED Pivotal trial demonstrated
the superiority of catheter-based renal denervation
compared with sham control to safely lower BP in the
absence of antihypertensive medications.
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